You are here

Positive Results Reported for Vortioxetine (Brintellix) in Adult Patients With Major Depression

Drug significantly more effective than comparator, agomelatine (Apr. 8)

Positive results have been reported from a European study of vortioxetine (Brintellix, Lundbeck) versus agomelatine in adults with major depression (MDD) who changed antidepressant treatment after an inadequate response to selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI) therapy.

The objective of this double-blind, randomized study was to compare the efficacy and tolerability of flexible-dose treatment with vortioxetine versus agomelatine in patients with MDD. Agomelatine was chosen as the comparator because of its different mode of action from that of conventional SSRI/SNRI drugs.

In the REVIVE trial, the primary efficacy endpoint was the change from baseline to week 8 in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score. Secondary endpoints included assessments of anxiety symptoms (Hamilton Anxiety Scale [HAM-A]); global clinical judgment (Clinical Global Impressions Scale–Severity [CGI-S] and Clinical Global Impressions Scale–Improvement [CGI-I]); and overall functioning (Sheehan Disability Scale [SDS]). Patients were randomly assigned to receive vortioxetine (10 to 20 mg/day) or agomelatine (25 to 50 mg/day) for 12 weeks.

On the primary efficacy endpoint, vortioxetine (n = 252) was significantly superior to agomelatine (n = 241) by 2.2 MADRS points (P P

Vortioxetine was well tolerated, with fewer patients withrawing from the vortioxetine group (5.9%) versus the agomelatine group (9.5%). Nausea was more common in vortioxetine-treated patients than in those given agomelatine (16% vs. 9%, respectively).

Vortioxetine is under investigation as a multimodal antidepressant that is thought to work through a combination of two complementary mechanisms of action: receptor activity modulation and reuptake inhibition. In vitro studies demonstrated that vortioxetine is a 5-HT3,5-HT7, and 5-HT1D receptor antagonist; a 5-HT1B receptor partial agonist; a 5-HT1A receptor agonist; and a serotonin transporter (SERT) inhibitor. In addition, in vivo nonclinical studies have shown that vortioxetine modulates neuronal firing and neurotransmitter release in multiple systems, resulting in enhanced levels of serotonin, noradrenaline, dopamine, acetylcholine, and histamine in specific areas of the brain.

The multimodal activity profile of vortioxetine differs from the activity profiles of currently available antidepressant drugs.

In 2012, vortioxetine (formerly known as Lu AA21004) was filed for regulatory approval for the treatment of MDD in the U.S.

Source: Lundbeck; April 8, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs